In a nationwide, population-based matched cohort study, researchers explored the risk for Parkinson disease and secondary parkinsonism among 1-year survivors of myocardial infarction.
Researchers compared calcium channel blockers with other classes of antihypertensive drugs to determine their ability to reduce incidence of major cardiovascular events.
People with myocardial infarction (MI) have a reduced risk for Parkinson disease and secondary parkinsonism during a median follow-up of 21 years.
Significantly faster declines in global cognition, memory, and executive function are seen following incident myocardial infarction (MI).
Researchers sought to examine the presence of CML and NOX2 proinflammatory factors in the brain microvasculature of patients with myocardial infarction.
Daily colchicine treatment may reduce the risk for cardiovascular events in patients with chronic coronary disease.
Researchers sought to determine whether triglyceride levels were independently associated with cardiovascular disease among patients with coronary artery disease and type 2 diabetes.
Evolocumab treatment in addition to statin therapy was found to lower cardiovascular risk in patients with metabolic syndrome and stable atherosclerotic cardiovascular disease.
The 510(k) clearance allows for modification of the labeling of the previously authorized pharmacogenetics report.
Low mean levels and high variability of HDL-C were found to be associated with increased risks for stroke, myocardial infarction and all-cause mortality.
